Increasing Ozempic Dose Linked to Lower Heart Risk Than Switching to Mounjaro

Recent research suggests that increasing your Ozempic dose may offer greater heart protection than switching to Mounjaro. Eva Kongshavn · Moment/Getty A real-world study found that people with type 2 diabetes who increased their Ozempic dose rather than switching to Mounjaro had a lower risk of major adverse cardiovascular events (MACE). Those who increased their Ozempic dose to 2 mg had a 6% lower risk of MACE than those who switched to Mounjaro. Because the study was observational, it showed an association and does not prove that increasing the Ozempic dose caused the lower cardiovascular risk. Increasing the dose of Ozempic rather than switching to Mounjaro may be associated with a lower risk of major adverse cardiovascular events (MACE), according to a 2026 insurance claims analysis presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. GLP-1 medications like semaglutide (Ozempic) and tirzepatide (Mounjaro) have reshaped care for people with type 2 diabetes, but recent real-world evidence suggests these drugs may not offer identical heart protection. It is important to keep in mind that this was a retrospective, observationa…

≈